Christopher Hite Sells Shares of Royalty Pharma plc $RPRX
Key Points
- Christopher Hite sold 150,000 shares of Royalty Pharma plc ($RPRX) worth $8.16 million.
- $RPRX last traded around $54.69.
Important disclosure: Podchat is not a registered investment adviser, broker-dealer, or financial planner. This article is for informational and educational purposes only and is not a recommendation to buy, sell, or hold any security. Content may be generated by automated systems using public filings, market data, and third-party sources, and may contain errors or omissions. Investing involves risk, including possible loss of principal. Past performance, insider activity, analyst ratings, price targets, sentiment scores, and hypothetical or backtested results are not guarantees of future performance. Please do your own research and consult a qualified professional before making investment decisions.
Christopher Hite, EVP & Chairman, Partnering at Royalty Pharma plc ($RPRX), sold 150,000 shares at an average price of $54.39, for a total transaction of $8.16 million. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Royalty Pharma plc Stock Down 10.1%
Shares of Royalty Pharma plc ($RPRX) traded around $54.69 on Friday, down 10.1% for the day.
Royalty Pharma plc Earnings
Royalty Pharma plc Dividend
Analysts Set New Price Targets
About Royalty Pharma plc
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.
Get Royalty Pharma plc alerts
New 13F filings, insider trades, and analyst moves on $RPRX, sent to your inbox. Free, and you can unsubscribe anytime.
This instant news alert was generated by automated narrative technology and financial data from Podchat and public regulatory filings. It is for informational purposes only and is not financial advice.